Status:
UNKNOWN
Microbiota, Sarcopenia, and Hepatic Encephalopathy Change in Cirrhotic Patients Before and After Rehabilitation
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Hepatic Encephalopathy
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Through this plan, it will provide many benefits to patients with liver cirrhosis complicated with sarcopenia and/or hepatic encephalopathy, their family members, and the government in Taiwan: 1. To ...
Detailed Description
Chronic liver disease is notorious as Taiwan's national disease and more than 4,000 patients died of liver cirrhosis each year in Taiwan. Hepatic encephalopathy (HE) manifests from minimal HE (MHE) to...
Eligibility Criteria
Inclusion
- Patients with liver cirrhosis
Exclusion
- unstable vital sign such as shock, coma or intubation status
- Non-curative hepatocellular carcinoma (cannot receive operation, radiofrequency ablation, liver transplantation,etc
- Un-curative malignancies
- Poor-controlled diabetes mellitus (HbA1C≧8)
- Active alcoholism (male alcohol ≧40g/day, or ≧140g/week; female ≧ 30g/day, or ≧70g/week
- Psychiatric comorbidities
- Neurologic comorbidities like Alzheimer's, Parkinson's, stroke with neurological deficit
- Unable to speak
- Bed-ridden status
- Post- Liver transplantation.
Key Trial Info
Start Date :
December 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06040814
Start Date
December 1 2022
End Date
November 30 2025
Last Update
September 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Taoyuan District, Taiwan, 333